Wall Street analysts expect The Medicines Company (NASDAQ:MDCO) to announce earnings of ($1.48) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for The Medicines’ earnings, with the highest EPS estimate coming in at ($1.11) and the lowest estimate coming in at ($1.72). The Medicines posted earnings per share of ($1.77) in the same quarter last year, which would indicate a positive year-over-year growth rate of 16.4%. The company is scheduled to issue its next earnings report on Tuesday, February 27th.

On average, analysts expect that The Medicines will report full-year earnings of ($8.86) per share for the current financial year, with EPS estimates ranging from ($9.10) to ($8.48). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.95) per share, with EPS estimates ranging from ($4.02) to ($3.87). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for The Medicines.

The Medicines (NASDAQ:MDCO) last posted its quarterly earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.95. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The business had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $26.06 million. During the same quarter in the prior year, the business earned ($0.64) EPS. The firm’s revenue for the quarter was down 55.1% on a year-over-year basis.

A number of brokerages have commented on MDCO. Zacks Investment Research raised The Medicines from a “sell” rating to a “buy” rating and set a $31.00 price objective on the stock in a report on Tuesday. ValuEngine raised The Medicines from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Oppenheimer raised The Medicines from a “market perform” rating to a “buy” rating and set a $50.00 price objective on the stock in a report on Wednesday, November 29th. Citigroup raised The Medicines from a “sell” rating to an “outperform” rating in a report on Thursday, November 30th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $54.00 price objective on shares of The Medicines in a report on Thursday, October 26th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $52.56.

The Medicines (MDCO) traded down $1.24 on Friday, reaching $27.14. The company had a trading volume of 1,271,416 shares, compared to its average volume of 1,018,725. The company has a current ratio of 2.31, a quick ratio of 1.79 and a debt-to-equity ratio of 3.42. The Medicines has a twelve month low of $25.40 and a twelve month high of $55.95. The company has a market cap of $2,068.82, a PE ratio of -2.97 and a beta of 0.71.

In related news, Director Alexander J. Denner bought 170,000 shares of The Medicines stock in a transaction dated Wednesday, November 29th. The shares were bought at an average cost of $30.03 per share, with a total value of $5,105,100.00. Following the acquisition, the director now owns 6,663 shares in the company, valued at approximately $200,089.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Clive Meanwell sold 136,250 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $27.24, for a total value of $3,711,450.00. Following the sale, the chief executive officer now directly owns 587,652 shares in the company, valued at $16,007,640.48. The disclosure for this sale can be found here. Corporate insiders own 8.22% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of The Medicines by 10.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $105,000 after purchasing an additional 264 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of The Medicines during the 3rd quarter worth $171,000. SG Americas Securities LLC acquired a new stake in shares of The Medicines during the 3rd quarter worth $198,000. Bluefin Trading LLC acquired a new stake in shares of The Medicines during the 2nd quarter worth $214,000. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of The Medicines by 4.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,058 shares of the company’s stock worth $230,000 after purchasing an additional 243 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “” was originally published by Equities Focus and is the sole property of of Equities Focus. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.equitiesfocus.com/2018/01/06/33575.html.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Get a free copy of the Zacks research report on The Medicines (MDCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply